Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis
- PMID: 16082639
- DOI: 10.1002/art.21337
Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis
Abstract
Objective: To develop a feasible magnetic resonance imaging (MRI)-based scoring system for spinal inflammation in patients with spondylarthropathy that requires minimal scan time, does not require contrast enhancement, evaluates the extent of lesions in 3 dimensional planes, and limits the number of vertebral levels that are scored because MRI demonstrates characteristic inflammatory lesions in the spine of patients with ankylosing spondylitis (AS) prior to the development of typical features on plain radiographic.
Methods: Our scoring method was based entirely on the assessment of increased signal denoting bone marrow edema on T2-weighted STIR sequences. Blinded MRI films were assessed in random order at 2 sites by 3 blinded readers at each of the 2 sites (the Universities of Alberta and Toronto). Intra- and interreader reliability was assessed by intraclass correlation coefficient. The 24-week response of patients with AS randomized to infliximab:placebo (8:3) was assessed by effect size and standardized response mean.
Results: An initial analysis of all discovertebral units (DVUs) in the spine of 11 patients demonstrated a mean of 3.2 (95% confidence interval 3.2, 5.2) affected units, while limiting the scoring to a maximum of 6 units captured most of the affected units. We scanned 11 patients with AS with clinically active disease and 20 additional patients randomized to a 24-week trial of either infliximab or placebo. Intraobserver reproducibility for the 6-DVU STIR score ranged from 0.93 to 0.98 (P < 0.0001). Interobserver reproducibility of scores by readers from both sites was 0.79 (P < 0.0001) for status score and 0.82 (P < 0.0001) for change score. Analysis of pretreatment and posttreatment scores for all 20 patients randomized to infliximab/placebo showed a large degree of responsiveness (standardized response mean = 0.87). Reproducibility and responsiveness were only slightly improved by using contrast enhancement with gadolinium diethylenetriaminepentaacetic acid.
Conclusion: The Spondyloarthritis Research Consortium of Canada MRI index is a feasible, reproducible, and responsive index for measuring spinal inflammation in AS.
Similar articles
-
Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis.Arthritis Rheum. 2005 Oct 15;53(5):703-9. doi: 10.1002/art.21445. Arthritis Rheum. 2005. PMID: 16208659 Clinical Trial.
-
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system.Arthritis Rheum. 2003 Apr;48(4):1126-36. doi: 10.1002/art.10883. Arthritis Rheum. 2003. PMID: 12687557 Clinical Trial.
-
Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study.J Rheumatol. 2010 Aug 1;37(8):1728-34. doi: 10.3899/jrheum.091043. Epub 2010 May 1. J Rheumatol. 2010. PMID: 20436073 Clinical Trial.
-
Is there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?J Rheumatol. 2007 Apr;34(4):871-3. J Rheumatol. 2007. PMID: 17407242
-
Magnetic resonance imaging in ankylosing spondylitis.Curr Opin Rheumatol. 2007 Jul;19(4):346-52. doi: 10.1097/BOR.0b013e32816a938c. Curr Opin Rheumatol. 2007. PMID: 17551364 Review.
Cited by
-
Male spondyloarthritis patients and those with longer disease duration have less severe disc degeneration: propensity score-matched comparison.Rheumatol Adv Pract. 2024 Feb 6;8(1):rkae015. doi: 10.1093/rap/rkae015. eCollection 2024. Rheumatol Adv Pract. 2024. PMID: 38405075 Free PMC article.
-
Validation of SPARCC MRI-RETIC e-tools for increasing scoring proficiency of MRI sacroiliac joint lesions in axial spondyloarth.RMD Open. 2024 Feb 13;10(1):e003923. doi: 10.1136/rmdopen-2023-003923. RMD Open. 2024. PMID: 38351052 Free PMC article. Clinical Trial.
-
Ixekizumab for Active Radiographic Axial Spondyloarthritis in Chinese Patients: 16- and 52-Week Results from a Phase III, Randomized, Double-Blind, Placebo-Controlled Study.BioDrugs. 2024 Jan;38(1):145-156. doi: 10.1007/s40259-023-00625-2. Epub 2023 Sep 22. BioDrugs. 2024. PMID: 37737952 Clinical Trial.
-
Changes of inflammation in patients with psoriatic arthritis after high intensity interval training assessed by ultrasound and MRI, a randomized controlled trial.BMC Musculoskelet Disord. 2023 Sep 19;24(1):743. doi: 10.1186/s12891-023-06871-3. BMC Musculoskelet Disord. 2023. PMID: 37726677 Free PMC article. Clinical Trial.
-
The correlations between C-reactive protein and MRI-detected inflammation in patients with axial spondyloarthritis: a systematic review and meta-analysis.Clin Rheumatol. 2023 Sep;42(9):2397-2407. doi: 10.1007/s10067-023-06658-w. Epub 2023 Jun 19. Clin Rheumatol. 2023. PMID: 37336841 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
